SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
source: pixabay.com

SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial

Since its inception, life sciences company Solid Biosciences Inc. has been working to develop treatment options for patients with Duchenne muscular dystrophy (DMD). According to a recent press release, the…

Continue Reading SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD
mohamed_hassan / Pixabay

This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Pamrevlumab is a first-in-class antibody that treats Duchenne muscular dystrophy (DMD) by inhibiting the effects and activity of connective tissue disorder growth factor (CTGF). It is being developed by FibroGen,…

Continue Reading This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Updates Available on Givinostat Clinical Development for DMD

During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…

Continue Reading Updates Available on Givinostat Clinical Development for DMD

The First Duchenne Muscular Dystrophy Patient Receives Gene Therapy Treatment in Pfizer’s Phase 3 Trial

The very first patient has just been dosed in Pfizer's Phase 3 clinical trial for Duchenne muscular dystrophy (DMD). The trial is called CIFFREO. This patient received the therapy at a…

Continue Reading The First Duchenne Muscular Dystrophy Patient Receives Gene Therapy Treatment in Pfizer’s Phase 3 Trial
Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD
Free-Photos / Pixabay

Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD

In early January 2021, biopharmaceutical company Avidity Biosciences ("Avidity") announced updates from its 2021 pipeline. Currently, Avidity is working to create a line of Antibody Oligonucleotide Conjugates (AOCs), therapeutic options…

Continue Reading Avidity Announces 2021 Pipeline Updates For DM1, FSHD, DMD
Joint Funding Partnership Announced to Promote Potential Bone Growth Therapy for DMD
source: pixabay.com

Joint Funding Partnership Announced to Promote Potential Bone Growth Therapy for DMD

Mesentech and CureDuchenne have announced a partnership that includes generous funding from the Charles H. Hood Foundation. The partnership has developed a targeted therapy for reversing bone wastage in boys…

Continue Reading Joint Funding Partnership Announced to Promote Potential Bone Growth Therapy for DMD

Duchenne Muscular Dystrophy Trial has Gotten the Go Ahead from the FDA to Continue Dosing

Solid Biosciences has just reported that the FDA has finally lifted the hold they had placed on their Phase I/II trial for Duchenne muscular dystrophy (DMD). This trial is called…

Continue Reading Duchenne Muscular Dystrophy Trial has Gotten the Go Ahead from the FDA to Continue Dosing
Ataluren Halts Disease Progression in Patients with nmDMD
HeungSoon / Pixabay

Ataluren Halts Disease Progression in Patients with nmDMD

This year, at the 2020 CNS-ICNA Conjoint Meeting, researchers identified ataluren as a potential treatment that inhibits disease progression for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Research suggests…

Continue Reading Ataluren Halts Disease Progression in Patients with nmDMD
This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy
rawpixel / Pixabay

This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy

According to CureDuchenne, two companies have began a collaboration in an effort to create new gene therapies for Duchenne muscular dystrophy (DMD). Ultragenyx and Solid Bioscience are both using their…

Continue Reading This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy
A New Precision-Medicine Therapy for Duchenne Muscular Dystrophy Recently Approved by the FDA, Nearing Approval in Canada
source: pixabay.com

A New Precision-Medicine Therapy for Duchenne Muscular Dystrophy Recently Approved by the FDA, Nearing Approval in Canada

A new treatment for Duchenne muscular dystrophy (DMD) has recently been approved by the FDA. The therapy is called viltolarsen and it was created by Nippon-Shinyaku and the National Center…

Continue Reading A New Precision-Medicine Therapy for Duchenne Muscular Dystrophy Recently Approved by the FDA, Nearing Approval in Canada
Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon
source: pixabay.com

Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon

As sourced from BioSpace: After 44 years of the legendary Jerry Lewis hosting the Jerry Lewis MDA Telethon to bring awareness to this disorder, his tradition will live on in…

Continue Reading Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon